In the second quarter of 2025, ImmunityBio (IBRX) reported $26.4M in revenue, representing a 60% increase from $16.5M in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA + BCG in BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without Papillary tumors. The 1H 2025 sales of $42.9M represents a 246% increase in unit volume during the first two quarters of 2025 since the J-code approval versus the last two quarters of 2024. The company ended the quarter with $153.7M in cash, cash equivalents and marketable securities as of June 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update
- ImmunityBio’s Novel Approach to Combat Lymphopenia: A Market Game-Changer?
- ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update
- ImmunityBio’s Strategic Advancements and Market Potential Justify Buy Rating
- ImmunityBio Approves 2025 Equity Incentive Plan